Collecting duct carcinoma: A single-institution retrospective study
Zhuoer Xie1, Siddhartha Yadav1, Christine M Lohse2
1Department of Oncology, Mayo Clinic, Rochester, MN.
Urologic Oncology
|November 9, 2021
Summary
Collecting duct carcinoma (CDC) is rare. Nephrectomy may benefit early-stage patients, but systemic therapies lack durable response in metastatic CDC. Further research is needed for this rare kidney cancer.
Area of Science:
- Urologic Oncology
- Renal Pathology
- Cancer Management
Background:
- Collecting duct carcinoma (CDC) is an exceptionally rare renal tumor.
- Limited clinical data exists for CDC, hindering effective management strategies.
Purpose of the Study:
- To evaluate the institutional experience with the management of collecting duct carcinoma.
- To analyze clinical data and outcomes for patients diagnosed with CDC.
Main Methods:
- Retrospective review of renal tumors in the Mayo Clinic Nephrectomy Registry.
- Identification and descriptive statistical analysis of CDC cases.
- Kaplan-Meier methodology for survival analysis (overall and metastasis-free).
Main Results:
- 21 CDC cases identified (0.2% incidence) between 1970-2018.
- Predominantly affects men (81%) with median age 57; 90% had high-grade disease at nephrectomy.
- Early recurrence (median 5.6 months) and metastases (median 5.1 months); median overall survival 1.5 years.
- Long-term survival (>10 years) observed in 4 patients with localized, small tumors undergoing nephrectomy.
- No durable response to systemic therapies in the metastatic setting.
Conclusions:
- Nephrectomy may offer long-term benefits for select M0 patients with small tumors.
- Early local recurrence and distant metastases are common post-nephrectomy.
- Current systemic therapies show limited efficacy for metastatic collecting duct carcinoma.
